ORLANDO — The generic lipid-lowering drug fenofibrate was associated with a significant reduction in progression of diabetic retinopathy and maculopathy, researchers reported.
Data from the Lowering Events in Non-proliferative Retinopathy in Scotland, the LENS trial, were presented at the American Diabetes Association Scientific Sessions and simultaneously published in NEJM Evidence.
“This is really a repurposing study of an old drug, fenofibrate. ... [Fenofibrate is] thought of as a conventional triglyceride-lowering drug but here used in the context of diabetic eye disease,”